Shares of STAAR Surgical (NASDAQ:STAA) have been assigned an average rating of “Hold” from the six brokerages that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $46.00.
A number of research firms have issued reports on STAA. Zacks Investment Research downgraded STAAR Surgical from a “buy” rating to a “hold” rating in a research note on Friday, August 2nd. BidaskClub downgraded STAAR Surgical from a “hold” rating to a “sell” rating in a research note on Wednesday, September 4th.
A number of hedge funds have recently added to or reduced their stakes in STAA. TimesSquare Capital Management LLC purchased a new position in shares of STAAR Surgical in the 2nd quarter worth approximately $29,997,000. Nuveen Asset Management LLC boosted its stake in shares of STAAR Surgical by 2,140.1% in the 2nd quarter. Nuveen Asset Management LLC now owns 738,169 shares of the medical instruments supplier’s stock worth $21,688,000 after buying an additional 705,217 shares during the last quarter. Ardsley Advisory Partners LP boosted its stake in shares of STAAR Surgical by 3,650.0% in the 2nd quarter. Ardsley Advisory Partners LP now owns 375,000 shares of the medical instruments supplier’s stock worth $11,018,000 after buying an additional 365,000 shares during the last quarter. Marshall Wace LLP boosted its stake in shares of STAAR Surgical by 167.0% in the 2nd quarter. Marshall Wace LLP now owns 538,154 shares of the medical instruments supplier’s stock worth $15,811,000 after buying an additional 336,624 shares during the last quarter. Finally, RE Advisers Corp purchased a new position in shares of STAAR Surgical in the 2nd quarter worth approximately $7,043,000. Institutional investors and hedge funds own 90.96% of the company’s stock.
STAA stock opened at $28.79 on Friday. The company has a market capitalization of $1.23 billion, a P/E ratio of 102.82 and a beta of 2.32. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.97 and a current ratio of 5.53. STAAR Surgical has a 52-week low of $21.70 and a 52-week high of $54.00. The business has a 50-day simple moving average of $30.99 and a two-hundred day simple moving average of $31.09.
STAAR Surgical (NASDAQ:STAA) last released its quarterly earnings results on Wednesday, July 31st. The medical instruments supplier reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.10 by $0.04. The business had revenue of $39.66 million during the quarter, compared to the consensus estimate of $40.10 million. STAAR Surgical had a return on equity of 12.81% and a net margin of 5.80%. As a group, sell-side analysts forecast that STAAR Surgical will post 0.33 earnings per share for the current fiscal year.
About STAAR Surgical
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.
Featured Story: Cost of Capital Explained
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.